193 related articles for article (PubMed ID: 23104723)
1. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Macaulay VM; Middleton MR; Protheroe AS; Tolcher A; Dieras V; Sessa C; Bahleda R; Blay JY; LoRusso P; Mery-Mignard D; Soria JC
Ann Oncol; 2013 Mar; 24(3):784-91. PubMed ID: 23104723
[TBL] [Abstract][Full Text] [Related]
2. A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.
Soria JC; Massard C; Lazar V; Ozoux ML; Mery-Mignard D; Deslandes A; Tolcher AW
Eur J Cancer; 2013 May; 49(8):1799-807. PubMed ID: 23485230
[TBL] [Abstract][Full Text] [Related]
3. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Rosen LS; Puzanov I; Friberg G; Chan E; Hwang YC; Deng H; Gilbert J; Mahalingam D; McCaffery I; Michael SA; Mita AC; Mita MM; Mulay M; Shubhakar P; Zhu M; Sarantopoulos J
Clin Cancer Res; 2012 Jun; 18(12):3414-27. PubMed ID: 22510349
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
Philip PA; Goldman B; Ramanathan RK; Lenz HJ; Lowy AM; Whitehead RP; Wakatsuki T; Iqbal S; Gaur R; Benedetti JK; Blanke CD
Cancer; 2014 Oct; 120(19):2980-5. PubMed ID: 25041791
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
Okusaka T; Ikeda M; Fukutomi A; Kobayashi Y; Shibayama K; Takubo T; Gansert J
Jpn J Clin Oncol; 2014 May; 44(5):442-7. PubMed ID: 24782485
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
Hensley ML; Maki R; Venkatraman E; Geller G; Lovegren M; Aghajanian C; Sabbatini P; Tong W; Barakat R; Spriggs DR
J Clin Oncol; 2002 Jun; 20(12):2824-31. PubMed ID: 12065559
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Kotasek D; Tebbutt N; Desai J; Welch S; Siu LL; McCoy S; Sun YN; Johnson J; Adewoye AH; Price T
BMC Cancer; 2011 Jul; 11():313. PubMed ID: 21791058
[TBL] [Abstract][Full Text] [Related]
10. Survival benefit with the combination of docetaxel, gemcitabine and erlotinib in advanced and/or metastatic pancreatic cancer patients.
Samelis GF; Ekmektzoglou K; Tsiakou A; Giannakaki S; Konstadoulakis M
Hepatogastroenterology; 2011; 58(110-111):1776-81. PubMed ID: 21940348
[TBL] [Abstract][Full Text] [Related]
11. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
Sangha R; Davies AM; Lara PN; Mack PC; Beckett LA; Hesketh PJ; Lau D; Li T; Perkins N; Gandara DR
J Thorac Oncol; 2011 Dec; 6(12):2112-9. PubMed ID: 21892109
[TBL] [Abstract][Full Text] [Related]
12. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Brana I; Calles A; LoRusso PM; Yee LK; Puchalski TA; Seetharam S; Zhong B; de Boer CJ; Tabernero J; Calvo E
Target Oncol; 2015 Mar; 10(1):111-23. PubMed ID: 24928772
[TBL] [Abstract][Full Text] [Related]
13. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.
Verschraegen CF; Arias-Pulido H; Lee SJ; Movva S; Cerilli LA; Eberhardt S; Schmit B; Quinn R; Muller CY; Rabinowitz I; Purdy M; Snyder D; Bocklage T
Ann Oncol; 2012 Mar; 23(3):785-790. PubMed ID: 21746804
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
15. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
[TBL] [Abstract][Full Text] [Related]
17. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Blessing JA; Degeest K; Abulafia O; Rose PG; Homesley HD
Gynecol Oncol; 2008 Jun; 109(3):323-8. PubMed ID: 18394689
[TBL] [Abstract][Full Text] [Related]
18. An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Jotte RM; Von Hoff DD; Braiteh F; Becerra CR; Richards DA; Smith DA; Garbo L; Stephenson J; Conkling PR; Robert-Vizcarrondo F; Chen J; Turner PK; Chow KH; Tai DF; Ilaria R
Invest New Drugs; 2015 Feb; 33(1):148-58. PubMed ID: 25260842
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Bay JO; Ray-Coquard I; Fayette J; Leyvraz S; Cherix S; Piperno-Neumann S; Chevreau C; Isambert N; Brain E; Emile G; Le Cesne A; Cioffi A; Kwiatkowski F; Coindre JM; Bui NB; Peyrade F; Penel N; Blay JY;
Int J Cancer; 2006 Aug; 119(3):706-11. PubMed ID: 16496406
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
Ramalingam SS; Spigel DR; Chen D; Steins MB; Engelman JA; Schneider CP; Novello S; Eberhardt WE; Crino L; Habben K; Liu L; Jänne PA; Brownstein CM; Reck M
J Clin Oncol; 2011 Dec; 29(34):4574-80. PubMed ID: 22025157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]